CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 42 enrolled
Drug / intervention
Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01290536
NCT01290536Phase 2Completed
CompareCT.gov

Safety Profile Assessment of TheraSphere® Yttrium-90 Glass Microspheres Used for Treatment of Metastatic Liver Disease From Primary Colorectal, Neuroendocrine, Cholangiocarcinoma, Melanoma, and Breast Cancers Refractory to Chemotherapy: A Pilot Study

Nicholas Fidelman, MD·interventional·Posted Feb 7, 2011·Updated Mar 1, 2019

In Brief

A Phase 2 clinical trial evaluating Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere) for Colorectal Neoplasms and 4 related conditions. Completed, enrolled 42 participants.

Detailed Summary

This is a prospective pilot study designed to document safety and efficacy of liver-directed therapy for colorectal, neuroendocrine, cholangiocarcinoma, melanoma, and breast cancer metastases to the liver using Yttrium-90 glass microspheres (TheraSphere).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Neoplasms, Neuroendocrine Tumors, Cholangiocarcinoma, Melanoma, Breast Cancer
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 7, 2011
Enrollment StartMay 1, 2010
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 15.4 years ago

Interventions

Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere)device

Administration of Yttrium-90 glass microspheres (TheraSphere) into the hepatic artery